LAUSR

Key Points Question Is treatment with a fingolimod dose of 0.5 mg or 0.25 mg superior to glatiramer acetate, 20 mg, in reducing relapse activity over 12 months in adult participants aged 18 to 65 years with relapsing-remitting multiple sclerosis? Findings In this randomized clinical trial of 1064 adult participants with relapsing-remitting multiple sclerosis, treatment with fingolimod, 0.5 mg, reduced the annualized relapse rate by 41%, and treatment with fingolimod, 0.25 mg, reduced the annualized relapse rate by 15% compared with glatiramer acetate. The safety of fingolimod therapy was consistent with the established safety profile. Meaning The study results suggested that fingolimod, 0.5 mg, demonstrated superior efficacy, confirming 0.5 mg to be the optimal dose for the treatment of patients with relapsing-remitting multiple sclerosis.